← Back to Screener
Alto Neuroscience Inc. (ANRO)
Price$26.06
Favorite Metrics
Price vs S&P 500 (26W)306.16%
Price vs S&P 500 (4W)7.28%
Market Capitalization$813.65M
All Metrics
Book Value / Share (Quarterly)$4.73
Cash Flow / Share (Quarterly)$-1.62
Price vs S&P 500 (YTD)40.45%
EPS (TTM)$-2.21
10-Day Avg Trading Volume0.41M
EPS Excl Extra (TTM)$-2.21
EPS (Annual)$-2.50
ROI (Annual)-37.68%
Cash / Share (Quarterly)$5.53
ROA (Last FY)-34.60%
EBITD / Share (TTM)$-2.31
Cash Flow / Share (Annual)$-1.62
P/B Ratio5.38x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$-1
ROA (TTM)-38.24%
EPS Incl Extra (Annual)$-2.50
Current Ratio (Annual)15.69x
Quick Ratio (Quarterly)15.58x
3-Month Avg Trading Volume0.31M
52-Week Price Return1124.52%
P/S Ratio (Annual)3874.53x
Asset Turnover (Annual)0.01x
52-Week High$27.50
EPS Excl Extra (Annual)$-2.50
26-Week Price Return310.14%
Quick Ratio (Annual)15.58x
13-Week Price Return50.35%
Total Debt / Equity (Annual)0.13x
Current Ratio (Quarterly)15.69x
Enterprise Value$656.152
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4374.76%
Cash / Share (Annual)$5.53
3-Month Return Std Dev83.44%
Net Income / Employee (TTM)$-1
ROE (Last FY)-40.56%
EPS Basic Excl Extra (Annual)$-2.50
Total Debt / Equity (Quarterly)0.13x
EPS Incl Extra (TTM)$-2.21
ROI (TTM)-41.47%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)1094.69%
Year-to-Date Return43.09%
5-Day Price Return13.71%
EPS Normalized (Annual)$-2.50
Net Profit Margin (Annual)-4374.76%
Month-to-Date Return13.30%
EBITD / Share (Annual)$-2.78
Operating Margin (Annual)-5740.95%
LT Debt / Equity (Annual)0.12x
LT Debt / Equity (Quarterly)0.12x
EPS Basic Excl Extra (TTM)$-2.21
P/B Ratio (Annual)3.66x
Book Value / Share (Annual)$4.73
Price vs S&P 500 (13W)49.67%
Beta1.48x
ROE (TTM)-48.16%
52-Week Low$2.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANROAlto Neuroscience Inc. | — | — | — | — | $26.06 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments guided by brain-based biomarkers. The company's pipeline includes multiple programs targeting major depressive disorder and schizophrenia, with candidates including ALTO-100, ALTO-202, ALTO-101, and ALTO-300. Alto's approach aims to match patients with treatments based on individual neurobiology to improve treatment efficacy in psychiatry.